Obermatt
See Similar Stocks →

Bio-Rad Laboratories

NYQ:BIO · US0905722072
Life Sciences Tools & ServicesLarge

360

48
EV / EBIT23
Price / Owner Earnings26
Owner Earnings Yield65
Dividend Yield1
Price/Sales56
EV / Gross Profit83
Price/Book74
Return on Capital35
Cash Return on Capital51
Return on Equity44
EBIT Margin47
Gross Profitability25
Cash Conversion85
Accruals48
Owner Earnings Margin59
Sales growth26
Profit Growth64
Long-Term EPS Growth7
Owner Earnings Growth18
Reinvestment51
Price momentum66
Debt load69
Refinancing85
Debt Payback100
Liquidity82
Analyst ratings5
Opinion Changes94
Price Target Upside15
Market mood35
Value Creation10/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Bio-Rad Laboratories clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
TypePublic Company
ExchangeNYSE
Founded1975
Employees6,129
Websitebio-rad.com
ISINUS0905722072
Last UpdateApr 2, 2026
Indices
S&P MIDCAP (USA)D.J. US Health Care
Themes
GeneticsBiomedical EngineeringHealth DiagnosticsBiotechnology

Description

Bio-Rad Laboratories, Inc. (‘Bio-Rad’), a multinational life science and clinical diagnostics company, develops, manufactures, and markets a broad portfolio of instruments, systems, reagents, and consumables. The company has direct operations in ove…

Analysis

Middle-of-the-road

Bio-Rad Laboratories, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

The price is expensive. You pay 42.8× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone.

The trajectory is tepid and the balance sheet is sturdy. The company scores 10/20 on our value-creation score: creating some value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
69
2023202420252026

All-time high

76

Mar 2026

All-time low

25

Jan 2025

Average rank

53

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
56
64
57
50
Price/Earnings
15
32
47
10
Price/Book
74
84
85
100
Dividend Yield
1
1
1
1
Value (overall)
32
61
60
49

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Bio-Rad Laboratories with its peers
Illumina
NSQ:ILMN
77
CountryUSA
IndustryLife Sciences Tools & Services
SizeX-Large
Full Stock Analysis →
Revvity
NYQ:RVTY
52
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Niagen Bioscience
NAQ:NAGE
71
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →
Bio-Techne
NSQ:TECH
74
CountryUSA
IndustryLife Sciences Tools & Services
SizeLarge
Full Stock Analysis →
Adaptive Biotechnologies
NSQ:ADPT
20
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Standard BioTools
NSQ:LAB
60
CountryUSA
IndustryLife Sciences Tools & Services
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →